Inflammation is a complex biological response of the body towards pathogens, damaged cells or any external foreign material. It is characterized by swelling, redness, pain and sometimes loss of function of the inflamed area. Inflammation is of two types: acute and chronic. Acute inflammations arise from cut or scrap in the skin or infections such as bronchitis which are short term in nature and its effects diminish after few days. Whereas chronic inflammations, are long term infections primarily seen in autoimmune diseases including allergies, asthma and rheumatoid arthritis (RA). Anti-inflammatory medications, commonly known as non-steroidal anti-inflammatory drugs (NSAIDs), are therapeutic drugs which are used to ease pain, reduced swelling and other long term chronic pains associated with inflammation. Whether, it is acute pain or chronic pain such as osteoarthritis, and even menstrual pain, these drugs give faster relief in comparison to other therapeutic drugs such as corticosteroids. NSAIDs induce anti-inflammatory response by lowering prostaglandin levels in the body, which is responsible for swelling and pain.
Growing prevalence of chronic diseases and autoimmune conditions is expected to propel the growth of the market. According to a report published by British Society for Immunology in March 2016, around 8,400 people in UK were affected by Addison’s disease, and approximately 127,000 were affected by metabolic syndromes. Furthermore, increasing geriatric population with high risk of developing various disorders is set to drive the demand for anti-inflammatory therapeutics. However, high risk of developing cardiovascular diseases with prolonged used of anti-inflammatory drugs and termination of leading patents will hamper the growth of the global market.
Anti-inflammatory drugs are prescribed to treat various inflammatory conditions such as arthritis and immune-mediated inflammatory diseases. Arthritis is inflammation of joints characterized by swelling, pain, stiffness, and restricted mobility. The symptoms can vary from mild, moderate to severe conditions. According to a study conducted by Arthritis Foundation, currently more than 50 million American adults have arthritis and this number is expected to increase to 67 million by 2030 whereas around 300,000 children have arthritis or some other form of rheumatic diseases. The risk of arthritis is more prevalent in women than men. Some form of arthritis especially rheumatoid arthritis increases risk of developing cardiovascular diseases and lung disorders besides causing permanent damage to joints and bones. Treatment for arthritis depends on severity of condition. Some form of arthritis can be treated with physiotherapy and surgery. However, most arthritis is managed by using NSAIDs drugs for reducing stiffness and pain. Some of the commonly used NSAIDs for managing inflammatory pain include meloxicam, diclofenac, and piroxicam. These anti-inflammatory drugs block cyclooxygenase, an enzyme that induces inflammatory response resulting in redness and pain.
Anti-inflammatory biologics is another major drug class used to treat inflammation. Biologics are genetically engineered protein derived from human genes which are used to induce anti-inflammatory response. Biologics are prescribed for people who don’t respond to any other treatment including use of NSAIDs. These biologics work by binding with Tumor necrosis factor alpha (TNF-alpha) to block the effect of TNF-alpha to induce anti-inflammatory response.
The major players operating in the global market are AbbVie Inc., GlaxoSmithKline, Eli Lilly and Company, F. Hoffmann-La Roche AG, Johnson & Johnson, Amgen, and Merck & Co Inc. Majority of these players are highly focused on the development of drugs related to untapped areas in order to gain competitive edge over other players in the market. For instance, in February 2016, Pfizer obtained FDA approval for its XELJANZ-XR (tofacitinib citrate) to treat severe rheumatoid arthritis. This medicine is particularly used to treat a patient that shows inadequate response to intolerance of methotrexate. XELJANZ-XR is first of its kind oral RA Treatment which inhibits activity of Janus kinase activity that will help Pfizer to gain competitive edge over other players in the market.
The key players are focusing on filing new patents owing to increase in number of patent expiry of leading drugs providing ample opportunity for growth in the market. Moreover with rapid development of novel metabolites having inflammatory properties will propel growth of the market in coming years. For instance, in recent years, a significant number of compounds (manoalide and pseudopterosins) have been extracted from marine organisms which have high concentration of bioactive materials which can induce strong anti-inflammatory response. Such developments are expected to drive the market in coming years.
Anti-Inflammatory Therapeutics Market Segmentation:
- Respiratory Diseases
- Multiple Sclerosis
- Inflammatory/Bowel Disease
- Other inflammatory Diseases
By Drug Class
- Anti-inflammatory Biologics
- Non-Steroidal Anti-inflammatory drugs (NSAIDs)
- Rest of Europe
- South Korea
- Rest of Asia-Pacific
- South Africa
- Saudi Arabia
- United Arab Emirates
We use both primary as well as secondary research for our market surveys, estimates and for developing forecast. Our research process commence by analyzing the problem which enable us to design the scope for our research study. Our research process is uniquely designed with enough flexibility to adjust according to changing nature of products and markets, while retaining core element to ensure reliability and accuracy in research findings. We understand both macro and micro-economic factors to evaluate and forecast different market segments.
Data is extensively collected through various secondary sources such as annual reports, investor presentations, SEC filings, and other corporate publications. We also refer trade magazines, technical journals, paid databases such as Factiva and Bloomberg, industry trade journals, scientific journals, and social media data to understand market dynamics and industry trends. Further, we also conduct primary research to understand market drivers, restraints, opportunities, challenges, and competitive scenario to build our analysis.
Data Collection Matrix
Data Collection Matrix
Primary Data Sources
- Distributors & Wholesalers
- Healthcare Providers
Secondary Data Sources
- Annual Reports/SEC Filings/ Investor Presentations/ Press Releases
- Government/Associations Publications
- Case Studies
- Reference Customers
Market Modeling and Forecasting
We use epidemiology and capital equipment-based models to forecast market size of different segments at country and regional level.
- Epidemiology-based Forecasting Model: This method uses epidemiology data gathered through various publications and from physicians to estimate population of patients, flow of treatment of individual disease and therapies. The data collected through this method includes statics on incidence of disease, population suffering from disease, and treatment population. This method is used to understand:
- Number of patients for particular device or medical procedure and
- Repeated use of particular device depending on health and condition of patient
- Capital-based Forecasting Model: This method of forecasting is based on number of replacements, installed-based and new sales of capital equipment used in various healthcare and diagnostic centers. These three parameters are calculated and forecast is developed. Installation base is calculated as average number of units per facility; while sales for particular year is calculated from number of new and replace units. Secondary data is collected through various supply chain intermediaries and opinion leaders to arrive at installation and sales rate. These techniques help our analysts in validating market and developed market estimates and forecast.
We do forecast on basis of several parameters such as market drivers, market opportunities, industry trends government regulations, raw materials supply and trade dynamics to ensure relevance of forecast with market scenario. With increasing need to granulized information, we used bottom-up methodology for forecasting where we evaluate each regional segment differently and combined all forecast to develop final market forecast.
We believe primary research is a very important tool in analyzing and forecasting different markets. In order to make sure accuracy of our findings, our team conducts primary interviews at every stage of research to gain deep insights into current business environment and future trends and key developments in market. This includes use of various methods such as telephonic interviews, focus groups, face to face interviews and questionnaires to validate our research from all aspects. We validate our data through primary research from key industry leaders such as CEO, product managers, marketing managers, suppliers, distributors, and consumers are frequently interviewed. These interviews provide valuable insights which help us to have better market understanding besides validating our estimates and forecast.
Quantitative Data (2017-2025)
- Market Dynamics (Drivers, Restraints, and Challenges)
- Industry Trend Analysis
- Market Opportunities
- Government Policies and Regulations, Patent Analysis, and Reimbursement Policies
- Porter’s Five Forces and PESTLE Analysis
- Key Developments and Competitive Landscape
- Market Assessment and Forecast
- Market Assessment and Forecast, By Product
- Market Assessment and Forecast, By Technology
- Market Assessment and Forecast, By Application
- Market Assessment and Forecast, By End User
- Market Assessment and Forecast, By Region/Country